Drug intelligence / Profile preview

CT103 (Cura Therapeutics)

Development stage: Preclinical
Lead developer: Cura Therapeutics
Modality: Recombinant Proteins and Enzymes
Administration: Intraventricular, Intracavitary

Overview

CT103 is an engineered recombinant protein being developed by Cura Therapeutics as an immunotherapy for the treatment of fibrotic diseases. Developed using Cura's proprietary platform technology, the candidate is designed to modulate immune pathways to address underlying fibrotic processes. As of early 2024, the program is in the discovery stage of preclinical development, and its specific molecular target and exact fibrotic indications remain undisclosed by the company.

Beyond the preview

Go deeper on CT103 (Cura Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT103 (Cura Therapeutics).

Explore the full profile